Healthcare providers were previously overtreating patients with breast cancer, giving many of them chemotherapy, explained Jesus Anampa, MD, MS, professor of Medicine at the Albert Einstein College of Medicine. 

Researchers on the TAILORx study randomized patients with intermediate-risk disease to receive chemotherapy plus endocrine therapy (standard of care) or endocrine therapy alone. Findings showed that endocrine therapy alone was noninferior for most patients, though women who were younger than 50 years old saw a benefit with the addition of chemotherapy. 

Anampa emphasized that these findings are particularly important as we move toward more biomarker-driven care in breast cancer.

Videos

One expert discusses findings from the TAILORx study.

Jesus Anampa, MD, MS

Articles

Should All Patients With Breast Cancer Get Chemotherapy?